|Mr. Jeffrey S. Aronin||Founder & Non-Exec. Chairman||N/A||N/A||1968|
|Mr. John Charles Jacobs M.B.A.||Pres, CEO & Director||N/A||N/A||1967|
|Ms. Susan L. Drexler CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1969|
|Mr. David Bradshaw||Head of Technical Operations||N/A||N/A||N/A|
|Ms. Sharon Goldbach||Head of Facilities Operations & Exec. Admin.||N/A||N/A||N/A|
|Ms. Lisa M. Caperelli||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Stephanie Wisdo J.D.||Gen. Counsel & Compliance Officer||N/A||N/A||N/A|
|Ms. Nancy Leone||Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Audrey Murphy||Head of HR||N/A||N/A||N/A|
|Dr. Jeffrey M. Dayno||Chief Medical Officer||N/A||N/A||1957|
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.